Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024746 | 1.00 | PIK3CD (0.37) | PIK3CDMEN1KMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL14801600 | 0.97 | PIK3CD (0.36) | PIK3CDMEN1KMT2AMAOAMAOB | |
| Bromide SCHEMBL14801362 | 0.97 | PIK3CD (0.36) | PIK3CDMEN1KMT2AMAOAMAOB | |
| SCHEMBL12305100 | 0.90 | HTR1B (0.39) | MAOAMAOBHTR1ADRD3 | |
| SCHEMBL12663243 | 0.89 | MEN1 (0.37) | PIK3CDMEN1KMT2APOLB | |
| SCHEMBL12131662 | 0.88 | LCK (0.34) | PIK3CDMEN1KMT2A | |
| SCHEMBL15800488 | 0.88 | LMNA (0.43) | PIK3CDMEN1KMT2AHRH3POLB | |
| SCHEMBL16592400 | 0.88 | MEN1 (0.33) | PIK3CDMEN1KMT2APOLB | |
| SCHEMBL16838261 | 0.88 | HSD17B10 (0.35) | PIK3CDMEN1KMT2A | |
| SCHEMBL1292539 | 0.87 | PIK3CD (0.43) | PIK3CDMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081927-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2021055612-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| EP-3140300-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INT GMBH (DE) | 2019-08-14 | — | — | EP | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7997718-B2 | Substrate having dye with dendrimer axial ligands disposed thereon | SILVERBROOK RESEARCH PTY LTD (AU) | 2011-08-16 | — | — | US | disclosed |
| US-7971986-B2 | Inkjet containing phthalocyanine dye with non-planar groups | SILVERBROOK RESEARCH PTY LTD (AU) | 2011-07-05 | — | — | US | disclosed |
| US-7423145-B2 | Method of minimizing absorption of visible light in ink compositions comprising infrared-absorbing macrocyclic cyanine dyes | SILVERBROOK RESEARCH PTY LTD (AU) | 2008-09-09 | — | — | US | disclosed |
| US-7417141-B2 | Cyanine dye having reduced visible absorption | SILVERBROOK RESEARCH PTY LTD (AU) | 2008-08-26 | — | — | US | disclosed |
| US-20080170103-A1 | ELONGATE BI-LITHIC PRINTHEAD WITH A SUPPORT MEMBER | SILVERBROOK RESEARCH PTY LTD | 2008-07-17 | — | — | US | disclosed |
| US-7367665-B2 | Metal-cyanine dye having axial ligands which reduce visible absorption | SILVERBROOK RESEARCH PTY LTD (AU) | 2008-05-06 | — | — | US | disclosed |
| US-20070299257-A1 | GALLIUM NAPHTHALOCYANINE DYE | SILVERBROOK RESEARCH PTY LTD. | 2007-12-27 | — | — | US | disclosed |
| US-20070266891-A1 | INK COMPRISING GALLIUM NAPHTHALOCYANINE DYE | SILVERBROOK RESEARCH PTY LTD | 2007-11-22 | — | — | US | disclosed |
| US-7278727-B2 | Method of minimizing absorption of visible light in infrared dyes | SILVERBROOK RESEARCH PTY LTD (AU) | 2007-10-09 | — | — | US | disclosed |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070044680-A1 | Inkjet ink comprising IR dye with a plurality of water-solubilizing alcohol substituents | SILVERBROOK RESEARCH PTY LTD | 2007-03-01 | — | — | US | disclosed |
| US-20070034113-A1 | Inkjet ink comprising gallium naphthalocyanine dye | SILVERBROOK RESEARCH PTY LTD | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | PIK3CD 112/4885MEN1 3831/4885KMT2A 1670/4885 |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | AADAC, MRPL21, HDAC6 | PIK3CD 4277/4885MEN1 3199/4885KMT2A 1789/4885 |
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885MEN1 1606/4885KMT2A 3287/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | PIK3CD 2008/4885MEN1 3947/4885KMT2A 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.